Cell therapies in clinical trials: Moving the needle forward
Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how we’re going to make them a reality.
2024 greatest T1D hits: A glance at this year’s achievements
While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D. This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D. Here are the […]
Breakthrough T1D T1D Fund Invests in vTv Therapeutics
With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin (TTP399), an adjunct therapy to insulin.
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now in human clinical trials.
Eli Lilly Acquires Breakthrough T1D T1D Fund Portfolio Company Protomer Technologies
Breakthrough T1D is excited to announce that the T1D Fund portfolio company Protomer Technologies, who is developing "smart" insulin, has been acquired by Eli Lilly.
Study: Disease-Modifying Therapies Needed to Offset Costs of Type 1 Diabetes
A new study commissioned by the Breakthrough T1D T1D Fund spotlights the high economic burden of type 1 diabetes (T1D) and the tremendous value of accelerating disease-modifying therapies. The study, released today, estimates the annual cost of T1D is more than $30 billion in the United States, where 1.6 million people are living with the […]
